The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | The current status and future of CAR-T therapy in R/R myeloma
Shebli Atrash, MD, Levine Cancer Institute & Atrium Health, Charlotte, NC, discusses the efficacy of CAR T-cell therapies, including idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), when compared to standard of care (SoC) treatment regimens for relapsed/refractory multiple myeloma (R/R MM). This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
